Making a noise about the silent killer

Our new report profiles atherosclerosis and how Cyclarity’s novel therapy could prove to be a game-changer.

Cardiovascular disease is the world’s biggest killer claiming an estimated 17.9 million lives each year [1]. A leading risk factor for CVD is high levels of low-density lipoprotein (LDL) cholesterol, a substance made up of fats and proteins which contributes to plaque build-up in the arteries. These plaque deposits narrow the arteries and make them less flexible, leading to a hardening of the arteries called atherosclerosis (from the Greek words for paste and hardened).

However, the danger does not end there; oxidised low-density lipoprotein (oxLDL) cholesterol is taken up by macrophages resulting in a foamy cytoplasmic froth that causes cell death. These dead cells form a necrotic core that can rupture leading to a thrombosis, heart attack or stroke. In addition, oxLDL triggers an inflammatory response that can irritate the blood vessels, promote the growth of plaques, and loosen those plaques, leading to the same devastating events.

Longevity.Technology: Atherosclerosis is a killer, and the risk factor can be lowered by healthy lifestyle choices and by lipid-lowering agents such as statins. However, a new platform is tackling atherosclerosis in a novel way – by using custom-engineered cyclodextrins to capture, and remove from cells, oxidised cholesterol derivatives. This process removes plaque from arterial walls leaving toxic foam cells rehabilitated into healthy, functional macrophages and the dangerous oxidised cholesterol safely excreted.

The company behind this platform is Cyclarity, which is based in state-of-the-art labs at the prestigious Buck Institute for Research on Aging in Novato, CA. Cyclarity’s lead candidate is a proprietary, custom-engineered, nontoxic cyclodextrin designed to achieve high affinity and high specificity for the oxidised cholesterol target, and we feel their technology is such a potential game-changer that we’ve partnered with them on a report into atherosclerosis and the promise of cyclodextrins.

Disease management to disease modification: removing plaque to undo atherosclerosis – read our FREE report here

An in-depth look at atherosclerosis, our report overviews the fight against this “silent killer” and examines the effectiveness of current interventions and the potential of Cyclarity’s approach, weighing both against the healthcare burden and death rate caused by atherosclerosis and CVD.

We review the current market and Cyclarity’s place in it, as well as discussing the need for the move from disease management to disease modification, and why Cyclarity is spearheading true disease-modifying treatments for age-related diseases.

We also evaluate Cyclarity as an investment opportunity and its relevance to the longevity industry, overviewing the company’s unique attributes that can help catalyse the global shift into an era of longevity.

We believe Cyclarity’s cyclodextrin platform addresses the limiting factors of previous therapies both from a scientific perspective and from a market perspective, and we’re delighted to share Cyclarity’s vision for a movement away from disease management to disease modification with our readers. One American has a heart attack approximately every 40 seconds – that’s nearly 5 people in the time it’s taken you to read this article – the time has come to change that.

Our report is absolutely free and in easy-to-navigate HTML – just click here to read it!

READ MORE: Constructively disruptive – Cyclarity CEO talks tackling atherosclerosis through disease reversal